BU-NOT-SET

CONTACT US
Women in leadership
  • Corporate
Eyes
Insight
The state of the oral solid dose development and manufacturing market
  • Drug product
Eyes
Insight
Characterising APIs is Essential for Combo Drug Formulations
  • Drug substance
Eyes
Insight
Outsourcing stability testing
  • Analytical chemistry
Eyes
Insight
Brexit: What’s next for UK pharma?
  • Industry trends
Eyes
Insight
Navigating approval filings choppy international waters
  • Drug substance
Eyes
Insight
Regulatory requirements for drug substances
  • Drug substance
Product check
Insight
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
White paper
  • Analytical chemistry
  • Drug product
Developing a robust dissolution method for low-dose formulations
Report
  • Sustainability
Sustainability report 2022
Insight
  • Drug product
  • Industry trends
Navigating the changing oral solid dose landscape
Insight
  • Drug product
  • Manufacturing
The opportunities and obstacles of filling and packaging pre-filled syringes
Insight
  • Drug product
  • Industry trends
Tips for facilitating a successful tech transfer between sponsor and CDMO
Insight
  • Drug product
  • Industry trends
Alternative drug delivery formulation & device expertise
Insight
  • Industry trends
The 3 key trends shaping the CDMO industry in 2023 and beyond
Insight
  • Drug product
  • Industry trends
Three challenges pharma companies can overcome when choosing the right OSD partner
Insight
  • Sustainability
Sustainable pharmaceutical supply chains with the Science Based Targets initiative